Sarepta Therapeutics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Corvallis OR United States (1980)

Organization Overview

First Clinical Trial
2003
NCT00244647
First Marketed Drug
2015
lenvatinib (lenvima)
First NDA Approval
2016
eteplirsen (Exondys 51)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AVI BioPharma | AVI BioPharma, Director, Clinical Operations | Jerry R. Mendell | Sarepta Therapeutics | Sarepta Therapeutics Inc. | Sarepta Therapeutics, Inc. | SAREPTA THERAPS INC